Suresh S. Ramalingam, MD, FASCO, Winship Canter Institute of Emery University, leads the discussion on the impact of overall survival data from the FLAURA trial treating advanced non-small cell lung cancer (NSCLC). Panelists include Byoung Chul Cho, MD, PhD, Yonsei Cancer Center at Yonsei University College of Medicine; Pasi A. Janne, MD, PhD, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Harvard University; and Johan F. Vansteenkiste, MD, PhD, Leuven University Hospital.
Targeted Therapies in Lung Cancer
As recapped by Ramalingam, we now have at least 5 different molecular targets that are FDA-approved therapies. Data on the FLAURA presented at the ESMO 2017 Conference included the overall survival being improved substantially—the median overall survival was 38.6 months compared to 31.8 months in the control group. This is statically and clinically significant, as it is the first time survival advancement with one tyrosine kinase inhibitor (TKI) compared to another TKI was seen in patients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer (NSCLC).
How This Fits into Clinical Practices
The FLAURA study now has confirmed osimertinib’s efficacy as a front-line agent for EGFR-mutated disease. In how this data fits into the treatment lens landscape, the trial reinforces the importance of using the most promising treatments first. It matters to a patient that they are treated with methods and drugs that are proven to have the most promise. With known improvement in overall survival, the FLAURA trial results further reinforce that practice matter.
Call to Action: To see the full Peer Exchange interview, please see the source below.